Global Conjunctivitis Drugs Market 2018-2024: Fluoroquinolones have a Dominant Market Share for Bacterial Conjunctivitis
DUBLIN, Sept. 10, 2018 /PRNewswire/ --
The "Global Conjunctivitis Drugs Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.
The Global Bacterial Conjunctivitis Drugs Market is estimated to witness a CAGR of 2.1% during the forecast period 2018-2024.
North America accounts for the largest share of the bacterial conjunctivitis market, followed by Europe, Asia Pacific, and Rest of the World. More than 40% of the market is occupied by North America, with the US being the major contributor to the market growth.
Based on drug classes, the market is segmented into fluoroquinolones, aminoglycosides, macrolides, and others. Fluoroquinolones have a dominant market share for bacterial conjunctivitis. However, this drug class is likely to reduce its market share by 7.2% by the end of 2024 due to weak research pipeline. The highest growth rate is witnessed by aminoglycosides, followed by macrolides. However, the loss of patent of blockbuster drugs, such as Moxeza, Besivance, Vigamox, and Zymaxid, has hampered the growth of the market.
Many blockbuster drugs are likely to lose their patents in the market, which in turn, has increased the advent of generic drugs with similar efficacy and less cost. This patent expiry is expected to show a negative impact on the company revenue and its market position. Other strategies used by the market players are acquisitions.
The report provides complete details about the usage and adoption rate of bacterial conjunctivitis drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth.
Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Topics Covered:
1 Industry Outlook
1.1 Industry Overview
1.1.1 Global Driver for Pharmaceutical Demand:
1.1.2 Pharmaceutical spending region wise
1.1.3 R&D pipeline in pharmaceutical industry
1.1.4 Top pharma drugs by sales in 2017 ($Million)
1.2 Industry Trends
1.3 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition - Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Trends of Bacterial Conjunctivitis Drugs Market
3.4 Related Markets
3.4.1 Contact lenses
3.4.1.1 Trends of Contact Lens Market
3.4.2 Oncology (Cancer) Drugs
3.4.3 Active pharmaceutical ingredients (APIs)
3.4.4 Over the counter drugs (OTC)
4 Market Outline
4.1 Market Segmentation
4.2 Porter 5(Five) Forces
4.3 PEST Analysis
5 Market Characteristics
5.1 Market Dynamics of Bacterial Conjunctivitis Drugs Market
5.1.1 Drivers
5.1.1.1 Increasing awareness among patient population about pink eye disease
5.1.1.2 Rising prevalence of bacterial conjunctivitis
5.1.2 Opportunities
5.1.2.1 Increasing clinical trials
5.1.3 Restraints
5.1.3.1 Expiry of patents for blockbuster drugs
5.1.3.2 Complex drug development process
5.1.4 DRO - Impact Analysis
5.1.5 Key Stakeholders
6 Application: Market Size and Analysis
6.1 Overview
6.2 Fluoroquinolones
6.3 Aminoglycosides
6.4 Macrolides
6.5 Others
7 Regions: Market Size and Analysis
7.1 Overview
7.2 North America
7.2.1 Overview
7.3 Europe
7.3.1 Overview
7.4 APAC
7.4.1 Overview
7.5 Rest of the World
7.5.1 Overview
8 Competitive Landscape
9 Vendor Profiles
9.1 Novartis AG
9.2 Valeant Pharmaceuticals International Inc.
9.3 Teva Pharmaceutical Industries Ltd.
9.4 Akron Inc
10 Companies to Watch For
10.1 Santen Pharmaceutical Co., Ltd.
10.2 Perrigo Company plc
10.3 Merck & Co.
10.4 Pfizer Inc.
10.5 Daiichi Sankyo, Inc.
10.6 Bayer AG
10.7 F. Hoffmann-La Roche
For more information about this reportvisit
https://www.researchandmarkets.com/research/xx9d9p/global?w=5
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article